1 Recommendations

1.1

Mirdametinib can be used as an option to treat symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) in children and young people aged 2 to 17 years. Mirdametinib can only be used if the company provides it according to the commercial arrangement.

1.2

Use the least expensive option of the suitable treatments (including mirdametinib and, if the person is over 3 years, selumetinib), having discussed the advantages and disadvantages of the available treatments with the person with the condition. Take account of administration costs, dosages, price per dose and commercial arrangements.

1.3

This recommendation is not intended to affect treatment with mirdametinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop. For children or young people, this decision should be made jointly by the healthcare professional, the child or young person, and their parents or carers.

What this means in practice

Mirdametinib must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Mirdametinib must be funded in England within 30 days of final publication of this guidance.

There is enough evidence to show that mirdametinib provides benefits and value for money, so it can be used routinely across the NHS in this population.

Mirdametinib would be used in the same way as selumetinib in clinical practice. This includes continued use after age 18 if treatment was started before age 18, in line with NHS England's commissioning position.

Why these recommendations were made

For children and young people aged 3 to 17 years with NF1, usual treatment in the NHS for symptomatic plexiform neurofibromas that cannot be removed by surgery is selumetinib. Selumetinib and mirdametinib are both mitogen-activated protein kinase (MEK) inhibitors with a similar mechanism of action. For this evaluation, the company asked for mirdametinib to be considered only for children and young people aged 2 to 17 years. This does not include everyone who it is licensed for.

Clinical trial evidence suggests that mirdametinib reduces the size of plexiform neurofibromas. But this is uncertain because the trial is small and the size and location of plexiform neurofibromas varies. Mirdametinib has not been directly compared with selumetinib in a clinical trial. But an indirect comparison suggests that overall response is similar between mirdametinib and selumetinib. It also suggests that mirdametinib may reduce the size of plexiform neurofibromas more than selumetinib, with fewer side effects, but this is uncertain.

Because selumetinib is only recommended for children and young people aged 3 to 17 years, no comparative evidence is available for children aged 2 to 3 years. But it is reasonable to assume that mirdametinib's treatment effect would be similar in this age group, because:

  • children aged 2 to 3 years are clinically similar to children aged 3 years and over

  • clinical experts advise that the treatment effect of mirdametinib would be unlikely to differ between these age groups.

Mirdametinib is likely to have a similar treatment effect as selumetinib, because:

  • they are both MEK inhibitors with a similar mechanism of action

  • there is no evidence to suggest a meaningful difference in treatment effect between them.

A cost comparison suggests that the costs for mirdametinib are similar to those for selumetinib. So, it can be used.

For all evidence, see the committee papers. For more information on NICE's evaluation of selumetinib, see the committee discussion section in NICE's highly specialised technologies guidance on selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 3 to 17 years.